- Home
- ORIC vs EU Comparison
ORIC vs EU Comparison
Compare ORIC & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- EU
- Stock Information
- Founded
- ORIC 2014
- EU 2009
- Country
- ORIC United States
- EU United States
- Employees
- ORIC N/A
- EU N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- ORIC Health Care
- EU Basic Materials
- Exchange
- ORIC Nasdaq
- EU Nasdaq
- Market Cap
- ORIC 362.9M
- EU 538.3M
- IPO Year
- ORIC 2020
- EU N/A
- Fundamental
- Price
- ORIC $11.03
- EU $2.98
- Analyst Decision
- ORIC Strong Buy
- EU Strong Buy
- Analyst Count
- ORIC 9
- EU 1
- Target Price
- ORIC $18.29
- EU $2.75
- AVG Volume (30 Days)
- ORIC 858.6K
- EU 3.3M
- Earning Date
- ORIC 08-11-2025
- EU 08-13-2025
- Dividend Yield
- ORIC N/A
- EU N/A
- EPS Growth
- ORIC N/A
- EU N/A
- EPS
- ORIC N/A
- EU N/A
- Revenue
- ORIC N/A
- EU $46,179,000.00
- Revenue This Year
- ORIC N/A
- EU $27.46
- Revenue Next Year
- ORIC N/A
- EU $140.12
- P/E Ratio
- ORIC N/A
- EU N/A
- Revenue Growth
- ORIC N/A
- EU N/A
- 52 Week Low
- ORIC $3.90
- EU $1.01
- 52 Week High
- ORIC $14.67
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- ORIC 64.08
- EU 65.93
- Support Level
- ORIC $10.60
- EU $2.52
- Resistance Level
- ORIC $11.57
- EU $2.93
- Average True Range (ATR)
- ORIC 0.57
- EU 0.18
- MACD
- ORIC -0.08
- EU -0.00
- Stochastic Oscillator
- ORIC 72.32
- EU 91.49
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.